

**MAY 11
IN THIS ISSUE**

Coverage by
Southern Cross
and Bioshares

BNC210 continues
to come up trumps

BNC105 data at
prestigious cancer
conference

Merck Serono
visit

BIONOMICS

NOW

check out the
Southern Cross
and Bioshares
Reports at
www.bionomics.com.au

Coverage of Bionomics by Southern Cross and Bioshares

Southern Cross Equities have released a report on Bionomics dated 11 April 2011.

On 1 April 2011 Bioshares (number 402) also made comment on Bionomics.

If you would like a copy of either of these research reports please refer to our website or contact Bionomics via **email to** investorrelations@bionomics.com.au or by calling **08 8354 6101**.

BNC210 continues to come up trumps

The just completed European Phase Ib trials provided the first evidence of efficacy by BNC210 in reducing anxiety in human subjects. In the most exciting data we have to date, BNC210 was shown to rapidly reduce induced panic symptoms in healthy volunteers when compared with placebo in a controlled environment. Importantly, it does so without the side effects that mar currently marketed treatments. Despite the drawbacks in existing anti-anxiety drugs, the market is estimated to be US\$5-12 billion globally.

CEO Report

Dear Shareholders


The recent exciting data for BNC210 continues to infer that this next-generation drug has significant competitive advantages over current treatments for the debilitating conditions of anxiety and depression.


The potential of this compound is creating a great deal of interest in Bionomics that is being reflected in its share price which has doubled since the start of the year.

In this update, I'll recap the BNC210 results to date as well as the status of our BNC105 anti-cancer program and our ongoing collaboration with Merck Serono.

**BIONOMICS LIMITED
SHARE PRICE FROM
3 JANUARY TO
13 APRIL, 2011**

REFERENCE: ASX:0.675





CONT: BNC210 continues to come up trumps

Two trials were conducted for Bionomics by Forenap Pharma in France in the past six months. The first trial in fifty nine subjects used a peptide called CCK to induce anxiety and a brief panic attack in fifteen otherwise healthy volunteers. There was a statistically significant reduction in the range and severity of symptoms after 10 minutes in BNC210 treated subjects. They also recovered much more rapidly than subjects on placebo, whose emotional stability did not return to normal until 60 minutes after the panic attack. This has enormous implications in the overall well-being of anxiety patients who live in fear of their next attack.

The second trial of twenty one healthy subjects compared BNC210 with Lorazepam, a benzodiazepine or Valium-like drug used to treat anxiety. **We now have the first clinical evidence of the complete lack of side effects on attention and memory by BNC210 that had been previously indicated by studies in animal models.** Causing no impairment, BNC210 clearly out-performed Lorazepam as evidenced by EEG readings and other tests measuring memory, sedation, addiction, attention and motor co-ordination.

All in all, the trials delivered significant key data that exceeded expectations and that are very encouraging for the further development of BNC210. We now turn our focus to seeking a partner for Phase II development of BNC210. We believe we are on track to secure a significant licensing deal and these outstanding results set us up well to execute that strategy.

BNC105 data at prestigious cancer conference supports ongoing clinical program

Bionomics' anti-cancer agent, BNC105 is in Phase II clinical trial for renal cancer in the US and for mesothelioma in Australia. We expect to report interim data on both of these trials later this quarter. In the meantime, our scientists have presented further data on the selective vascular disruption activity of BNC105 at the annual American Association for Cancer Research (AACR) conference in Orlando, USA. Our two poster presentations were well received. One showed that BNC105 induced tumour blood vessel shutdown in both the primary renal tumour and secondary lung cancer in mouse models. BNC105 activity was shown to be comparable to that of the blockbuster drug Sutent which had worldwide sales of US\$1.066 billion in 2010.

In the second poster, the survival benefit of BNC105 treatment in a mouse model of mesothelioma surpassed that of Alimta, the leading treatment for human mesothelioma. These data further demonstrate that **BNC105 is a VDA that rapidly shuts down existing and new tumour blood vessels with no effect on normal blood vessels which augers well for its effectiveness against both primary and secondary solid tumours.**

Merck Serono visit

In March Merck Serono scientists from Geneva spent valuable time at Bionomics' headquarters in Adelaide. Meeting us on our home turf, the visit was a great opportunity to showcase our drug discovery platforms and state-of-the-art facilities to our collaborators. Bionomics first partnered its Kv1.3 programme with Merck Serono in June 2008 which, in May 2010 extended its commitment to fully fund the further development of potential Multiple Sclerosis drugs from the programme.

On the strength of the BNC210 results, Bionomics was invited to present at Needham & Company's 10th Annual Healthcare Conference in New York in early April. It was a privilege to be able to address this high impact forum that assembles some of the most dynamic companies in the biotechnology space and the invitation reflects our growing stature on the world scene.

Dr Deborah Rathjen
Chief Executive Officer

Contact Bionomics
31 Dalgleish Street
Thebarton, SA 5031
Australia
Tel: +61 8 8354 6101
Deborah Rathjen
CEO & Managing
Director
drathjen@bionomics.com.au

See Bionomics

3 – 7 June, 2011
ASCO Conference,
Chicago, USA

23 June, 2011
Australian
Biotech on Show
New York, USA

27 – 30 June, 2011
BIO International
Convention
Washington DC, USA



In the news

sky NEWS BUSINESS

Significant milestones and positive results achieved for BNC210. Video of this Sky News Business Channel story is available for viewing on our home page at www.bionomics.com.au



email us
and receive
your Bionomics
newsletter via
eNewsletter
investorrelations@bionomics.com.au

Factors Affecting Future Performance This publication contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this publication that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105 and BNC210, its drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this publication.



Enquiries:

Bionomics Limited

ABN 53 075 582 740

Dr Deborah Rathjen

CEO & Managing Director

Telephone: +618 8354 6101

drathjen@bionomics.com.au



ASX ANNOUNCEMENT: 4 May 2011

BIONOMICS SELLS THEBARTON PREMISES TO SUBSTANTIALLY BOOST CASH RESERVES

4 May 2011, Adelaide, Australia:

Bionomics Limited (ASX: BNO; ADR: BMICY) has entered into a contract to sell its head office and research facility in Thebarton, South Australia.

Subject to completion of the usual legal requirements, settlement will occur on 13 July 2011. Concurrent with the sale Bionomics has entered into a long term leaseback arrangement with the purchaser for a 10 year period with 2 x 5 year options to extend thereafter.

After repayment of debt secured by the premises and payment of transaction costs, Bionomics expects to receive a net cash inflow of \$4.27 million

on settlement. Bionomics' cash position at the end of the March 2011 quarter was \$5.79m.

The sale and leaseback will free up substantial additional working capital to further support Bionomics' clinical programs and the commercialisation of its key drug discoveries through its partnership strategy.

Shareholders are aware that Bionomics is seeking to complete its first, major partnering deal before the end of this calendar year and the additional resources from the disposal of the building will provide the Company with more than enough financial resources to achieve this goal.